Cargando…

The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges

Psychedelics or serotonergic hallucinogens are a group of substances that share the agonism of serotonergic 5-HT(2A) receptors as their main mechanism of action. Its main effects include changes in perception, cognitive process, and mood. Despite being used for centuries by different cultures in rit...

Descripción completa

Detalles Bibliográficos
Autores principales: dos Santos, Rafael Guimarães, Bouso, José Carlos, Rocha, Juliana Mendes, Rossi, Giordano Novak, Hallak, Jaime E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943545/
https://www.ncbi.nlm.nih.gov/pubmed/33707976
http://dx.doi.org/10.2147/RMHP.S300656
_version_ 1783662517429469184
author dos Santos, Rafael Guimarães
Bouso, José Carlos
Rocha, Juliana Mendes
Rossi, Giordano Novak
Hallak, Jaime E
author_facet dos Santos, Rafael Guimarães
Bouso, José Carlos
Rocha, Juliana Mendes
Rossi, Giordano Novak
Hallak, Jaime E
author_sort dos Santos, Rafael Guimarães
collection PubMed
description Psychedelics or serotonergic hallucinogens are a group of substances that share the agonism of serotonergic 5-HT(2A) receptors as their main mechanism of action. Its main effects include changes in perception, cognitive process, and mood. Despite being used for centuries by different cultures in ritual contexts, these substances have currently aroused the interest of science and industry for their promising antidepressant, anxiolytic, and anti-addictive effects. Considering this evidence, this article aims to explore some of the possible health policy challenges to integrate these therapeutic tools into broad and heterogeneous health systems. As a main benefit, these substances produce rapid and enduring effects with the administration of single or few doses, which could lead to new treatment possibilities for patients with severe mental disorders resistant to the usual medications. The main challenge is associated with the fact that these substances remain scheduled in most countries and are associated with social stigma related to their recreational use (especially LSD and psilocybin). This situation makes it exceedingly difficult to conduct clinical trials, although international conventions allow such research. Ethically, this could be interpreted as a violation of human rights since thousands of people are prevented from having access to possible benefits. Interestingly, ritual ayahuasca use is more acceptable to the public than the use of psilocybin-containing mushrooms or LSD. The controlled, clinical use of LSD and psilocybin seems to be less criticized and is being explored by the industry. Rigorous scientific evidence coupled with industrial interests (LSD and psilocybin), together with respect for traditional uses (ayahuasca) and international conventions, seems to be the best way for these drugs to be integrated into health systems in the next years. Which highlights the need for an urgent dialogue between science, health system, society, and politics.
format Online
Article
Text
id pubmed-7943545
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-79435452021-03-10 The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges dos Santos, Rafael Guimarães Bouso, José Carlos Rocha, Juliana Mendes Rossi, Giordano Novak Hallak, Jaime E Risk Manag Healthc Policy Review Psychedelics or serotonergic hallucinogens are a group of substances that share the agonism of serotonergic 5-HT(2A) receptors as their main mechanism of action. Its main effects include changes in perception, cognitive process, and mood. Despite being used for centuries by different cultures in ritual contexts, these substances have currently aroused the interest of science and industry for their promising antidepressant, anxiolytic, and anti-addictive effects. Considering this evidence, this article aims to explore some of the possible health policy challenges to integrate these therapeutic tools into broad and heterogeneous health systems. As a main benefit, these substances produce rapid and enduring effects with the administration of single or few doses, which could lead to new treatment possibilities for patients with severe mental disorders resistant to the usual medications. The main challenge is associated with the fact that these substances remain scheduled in most countries and are associated with social stigma related to their recreational use (especially LSD and psilocybin). This situation makes it exceedingly difficult to conduct clinical trials, although international conventions allow such research. Ethically, this could be interpreted as a violation of human rights since thousands of people are prevented from having access to possible benefits. Interestingly, ritual ayahuasca use is more acceptable to the public than the use of psilocybin-containing mushrooms or LSD. The controlled, clinical use of LSD and psilocybin seems to be less criticized and is being explored by the industry. Rigorous scientific evidence coupled with industrial interests (LSD and psilocybin), together with respect for traditional uses (ayahuasca) and international conventions, seems to be the best way for these drugs to be integrated into health systems in the next years. Which highlights the need for an urgent dialogue between science, health system, society, and politics. Dove 2021-03-05 /pmc/articles/PMC7943545/ /pubmed/33707976 http://dx.doi.org/10.2147/RMHP.S300656 Text en © 2021 dos Santos et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
dos Santos, Rafael Guimarães
Bouso, José Carlos
Rocha, Juliana Mendes
Rossi, Giordano Novak
Hallak, Jaime E
The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges
title The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges
title_full The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges
title_fullStr The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges
title_full_unstemmed The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges
title_short The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges
title_sort use of classic hallucinogens/psychedelics in a therapeutic context: healthcare policy opportunities and challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943545/
https://www.ncbi.nlm.nih.gov/pubmed/33707976
http://dx.doi.org/10.2147/RMHP.S300656
work_keys_str_mv AT dossantosrafaelguimaraes theuseofclassichallucinogenspsychedelicsinatherapeuticcontexthealthcarepolicyopportunitiesandchallenges
AT bousojosecarlos theuseofclassichallucinogenspsychedelicsinatherapeuticcontexthealthcarepolicyopportunitiesandchallenges
AT rochajulianamendes theuseofclassichallucinogenspsychedelicsinatherapeuticcontexthealthcarepolicyopportunitiesandchallenges
AT rossigiordanonovak theuseofclassichallucinogenspsychedelicsinatherapeuticcontexthealthcarepolicyopportunitiesandchallenges
AT hallakjaimee theuseofclassichallucinogenspsychedelicsinatherapeuticcontexthealthcarepolicyopportunitiesandchallenges
AT dossantosrafaelguimaraes useofclassichallucinogenspsychedelicsinatherapeuticcontexthealthcarepolicyopportunitiesandchallenges
AT bousojosecarlos useofclassichallucinogenspsychedelicsinatherapeuticcontexthealthcarepolicyopportunitiesandchallenges
AT rochajulianamendes useofclassichallucinogenspsychedelicsinatherapeuticcontexthealthcarepolicyopportunitiesandchallenges
AT rossigiordanonovak useofclassichallucinogenspsychedelicsinatherapeuticcontexthealthcarepolicyopportunitiesandchallenges
AT hallakjaimee useofclassichallucinogenspsychedelicsinatherapeuticcontexthealthcarepolicyopportunitiesandchallenges